Ocrelizumab approved by Medsafe
Media Release – 22 December 2017 The Multiple Sclerosis Society of New Zealand (MSNZ) is pleased that Medsafe[1] has approved the registration of ocrelizumab (Ocrevus®) for both Relapsing (RMS) and Primary Progressive (PPMS) multiple sclerosis (MS) in New Zealand. Earlier this year MSNZ made two submissions to PHARMAC to request the inclusion of ocrelizumab […]